CA2385381A1 - Gene de susceptibilite pour des affections intestinales inflammatoires - Google Patents
Gene de susceptibilite pour des affections intestinales inflammatoires Download PDFInfo
- Publication number
- CA2385381A1 CA2385381A1 CA002385381A CA2385381A CA2385381A1 CA 2385381 A1 CA2385381 A1 CA 2385381A1 CA 002385381 A CA002385381 A CA 002385381A CA 2385381 A CA2385381 A CA 2385381A CA 2385381 A1 CA2385381 A1 CA 2385381A1
- Authority
- CA
- Canada
- Prior art keywords
- ccr5
- delta
- inflammatory bowel
- bowel disease
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 title abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 67
- 238000012216 screening Methods 0.000 claims abstract description 29
- 108700028369 Alleles Proteins 0.000 claims abstract description 24
- 238000012217 deletion Methods 0.000 claims abstract description 23
- 230000037430 deletion Effects 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 51
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 50
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 230000002068 genetic effect Effects 0.000 claims description 9
- 230000003834 intracellular effect Effects 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 5
- 230000037433 frameshift Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000001502 gel electrophoresis Methods 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000010222 PCR analysis Methods 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims description 3
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims description 2
- 230000009460 calcium influx Effects 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 abstract description 37
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 27
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 26
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 4
- 108700011778 CCR5 Proteins 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 11
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000003205 genotyping method Methods 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003234 polygenic effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102200097908 rs1799864 Human genes 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 102000004274 CCR5 Receptors Human genes 0.000 description 1
- 101150017501 CCR5 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Il est possible d'établir une relation entre une délétion 32bp du gène humain codant pour le récepteur CCR5 de la chémokine, et le développement d'une affection intestinale inflammatoire (IBD), en particulier la maladie de Crohn' et la colite ulcéreuse. L'invention concerne des techniques permettant de diagnostiquer une susceptibilité à IBD, et d'établir une distinction entre la maladie de Crohn et la colite ulcéreuse, ce qui implique la détection de l'allèle CCR5-.DELTA.32 chez des patients qui en souffrent ou qui sont suspectés de développer une IBD. L'invention concerne également des techniques de criblage appropriées pour identifier des molécules ayant un potentiel en tant qu'agents thérapeutiques contre une IBD.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB1999/003192 WO2001021832A1 (fr) | 1999-09-23 | 1999-09-23 | Gene de susceptibilite pour des affections intestinales inflammatoires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2385381A1 true CA2385381A1 (fr) | 2001-03-29 |
Family
ID=10847634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002385381A Abandoned CA2385381A1 (fr) | 1999-09-23 | 1999-09-23 | Gene de susceptibilite pour des affections intestinales inflammatoires |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU6104699A (fr) |
| CA (1) | CA2385381A1 (fr) |
| GB (1) | GB2371622A (fr) |
| WO (1) | WO2001021832A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101943311B (zh) * | 2010-08-23 | 2012-12-26 | 广东爵仕泳池水疗设备有限公司 | 一种多功能电视支架 |
| RU2563172C1 (ru) * | 2014-11-12 | 2015-09-20 | Общество с ограниченной ответственностью "Покровский банк стволовых клеток" | СПОСОБ ОПРЕДЕЛЕНИЯ АЛЛЕЛЬНОГО ПОЛИМОРФИЗМА CCR5 delta 32 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69731373T2 (de) * | 1996-03-01 | 2006-03-09 | Euroscreen S.A. | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen |
| WO1998005798A1 (fr) * | 1996-08-08 | 1998-02-12 | The Aaron Diamond Aids Research Center | Mutants co-recepteurs du vih |
| AU6271598A (en) * | 1997-02-06 | 1998-08-26 | Epoch Pharmaceuticals, Inc. | Targeted modification of the ccr-5 gene |
| EP1039899A2 (fr) * | 1997-12-19 | 2000-10-04 | Takeda Chemical Industries, Ltd. | Composition pharmaceutique antagoniste de ccr5 et contenant un derive d'anilide |
-
1999
- 1999-09-23 CA CA002385381A patent/CA2385381A1/fr not_active Abandoned
- 1999-09-23 WO PCT/GB1999/003192 patent/WO2001021832A1/fr not_active Ceased
- 1999-09-23 AU AU61046/99A patent/AU6104699A/en not_active Abandoned
- 1999-09-23 GB GB0206993A patent/GB2371622A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2371622A (en) | 2002-07-31 |
| GB0206993D0 (en) | 2002-05-08 |
| AU6104699A (en) | 2001-04-24 |
| WO2001021832A1 (fr) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lehrnbecher et al. | Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations | |
| Scheffer et al. | Best practice guidelines for molecular analysis in spinal muscular atrophy | |
| Eikenboom et al. | Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD | |
| Bernardi et al. | A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype | |
| Badenhoop et al. | TNF-α gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus | |
| JP2975023B2 (ja) | Ｉ型糖尿病素因の診断用プローブ | |
| US6387615B2 (en) | Methods and materials for the diagnosis or prognosis of asthma | |
| US20090269761A1 (en) | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof | |
| US20170152565A1 (en) | Method for diagnosing renal diseases or predispositions | |
| Chung et al. | Gm (23) allotypes and Fcγ receptor genotypes as risk factors for various forms of periodontitis | |
| Craggs, S. West, A. Curtis, M. Welfare, M. Hudson, P. Donaldson, J. Mansfield | Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England | |
| Umamaheswaran et al. | Genetic analysis of OCT1 gene polymorphisms in an Indian population | |
| Wang et al. | A hypermorphic SP1-binding CD24 variant associates with risk and progression of multiple sclerosis | |
| Peng et al. | TLR1 polymorphisms are significantly associated with the occurrence, presentation and drug-adverse reactions of tuberculosis in Western Chinese adults | |
| Cohen et al. | The C3b/C4b receptor (CR1, CD35) on erythrocytes: methods for study of the polymorphisms | |
| Kato et al. | Single nucleotide polymorphisms in the coding regions of human CXC-chemokine receptors CXCR1, CXCR2 and CXCR3 | |
| Giardina et al. | The psoriasis genetics as a model of complex disease | |
| Grünhage et al. | Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C | |
| Worwood | Haemochromatosis | |
| Herrera et al. | Restriction fragment length polymorphism in HLA class II genes of Latin-American Caucasian celiac disease patients | |
| US20090011407A1 (en) | Polymorphic Cd24 Genotypes that are Predictive of Multiple Sclerosis Risk and Progression | |
| CA2385381A1 (fr) | Gene de susceptibilite pour des affections intestinales inflammatoires | |
| Delfan et al. | Association of HLA-DR2-related haplotype (HLA-DRB5* 01-DRB1* 1501-DQB1* 0602) in patients with multiple sclerosis in Khuzestan province | |
| Kageyama et al. | Polymorphism of CCR5 affecting HIV disease progression in the Japanese population | |
| Nookhai et al. | Prevalence of CCR2–64I, SDF1–3′ A and CCR5‐Δ32 alleles in healthy Thais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |